Pregabalin for painful diabetic peripheral neuropathy: Strategies for dosing, monotherapy vs. combination therapy, treatment-refractory patients, and adverse events

Current Medical Research and Opinion

Volumn 31, Issue 5, 2015, Pages 1017-1026

  Juhn, Mark S ^a   Parsons, Bruce ^a   Varvara, Roxanna ^a   Sadosky, Alesia ^a  

^a PFIZER INC   (United States)

Author keywords

Diabetic neuropathy; Painful diabetic peripheral neuropathy; Pregabalin; Primary care physician; Treatment strategy

Indexed keywords

DULOXETINE; GABAPENTIN; LIDOCAINE; PREGABALIN; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT;

CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; DIABETIC NEUROPATHY; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; EUROPEAN UNION; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS (TOPIC); PERIPHERAL EDEMA; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; UNITED STATES; WEIGHT CHANGE; WEIGHT GAIN; ANALOGS AND DERIVATIVES; DIABETIC NEUROPATHIES; DOSE RESPONSE; DRUG COMBINATION; TREATMENT OUTCOME;

ANALGESICS; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GAMMA-AMINOBUTYRIC ACID; HUMANS; TREATMENT OUTCOME;

EID: 84928192805     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1030375     Document Type: Review

References (62)

1. Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009;9:71-8
2. Vinik A. The approach to the management of the patient with neuropathic pain. J Clin Endocrinol Metab 2010;95:4802-11
3. Abbott CA, Malik RA, van Ross ERE, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220-4
4. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008;8:45-56
5. Sadosky A, Hopper J, Parsons B. Painful diabetic peripheral neuropathy: results of a survey characterizing the perspectives and misperceptions of patients and healthcare practitioners. Patient 2014;7:107-14
6. Ritzwoller DP, Ellis JL, Korner EJ, et al. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Curr Med Res Opin 2009;25:1319-28
7. Berger A, Sadosky A, Dukes E, et al. Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort study. BMC Neurol 2012;12:8
8. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes 2013;6:79-92
9. daCosta DiBonaventura M, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. Pain Med 2011;12:118-26
10. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790-5
11. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med 2007;49:672-9
12. Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010;11:360-8
13. Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007;8(Suppl 2):S50-62
14. Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010; 149:338-44
15. Gore M, Brandenburg NA, Dukes E, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005;30:374-85
16. Sachedina S, Toth C. Association of comorbidities with increasing severity of peripheral neuropathy in diabetes mellitus. World J Diabetes 2013;4:135-44
17. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? Pain 2010;149:194-201
18. Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 2014;14:167-84
19. US Lyrica Label [Lyrica US prescribing information]. New York, NY: Pfizer Inc., 2013. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id561 [Last accessed 16 April 2014]
20. EMA Lyrica Label [Lyrica European prescribing information]. Sandwich, Kent, UK: Pfizer Limited, 2013. Available at: http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/000546/ WC500046602.pdf [Last accessed 7 May 2014]
21. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758-65
22. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis Lancet Neurol 2015;14:162-73
23. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17: 1113-e88
24. Page N, Deluca J, Crowell K. Clinical inquiry: what medications are best for diabetic neuropathic pain? J Fam Pract 2012;61:691-3
25. Roth T, van Seventer R, Murphy TK. The effect of pregabalin on painrelated sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin 2010;26:2411-19
26. Vinik A, Emir B, Parsons B, Cheung R. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia. Pain Med 2014;15:661-70
27. Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther 2013;35:612-23
28. Hurley RW, Lesley MR, Adams MC, et al. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med 2008;33:389-94
29. Freeman R, Durso-DeCruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31:1448-54
30. Freynhagen R, Serpell M, Emir B, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract 2013: published online 27 November 2013, doi: 10.111/papr.12146
31. Ogawa S, Satoh J, Arakawa A, et al. Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west. Drug Saf 2012;35:793-806
32. Toth C. Drug safety evaluation of pregabalin. Expert Opin Drug Saf 2012;11:487-502
33. Tölle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:203-13
34. Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008;8:33
35. Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med 2011;28:109-16
36. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-60
37. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. Pain 2005;115:254-63
38. Stacey BR, Dworkin RH, Murphy K, et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008;9:1202-8
39. Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain 2011;27:185-93
40. Guan Y, Ding X, Cheng Y, et al. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. Clin Ther 2011;33:159-66
41. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104-10
42. Happich M, Schneider E, Boess FG, et al. Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study. Clin J Pain 2014;30:875-85
43. Hall GC, Morant SV, Carroll D, et al. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Fam Pract 2013;14:28
44. Tesfaye S, Vileikyte L, Rayman G, et al.; on behalf of the Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011: published online 21 June 2011, doi: 10.1002/ dmrr.1225
45. Zin CS, Nissen LM, O'Callaghan JP, et al. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain 2010;11:462-71
46. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in postherpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009;25:1677-87
47. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The 'COMBO-DN study'-a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013;154:2616-25
48. Ten Eyck L, Sadosky A, Ellis J, et al. Potential drug-drug interactions and opioid use among painful diabetic peripheral neuropathy Medicare members newly started on pregabalin or duloxetine. Presented at the 74th annual meeting of the American Diabetes Association, 13-17 June 2014, San Francisco, CA, USA
49. Sadosky A, Ellis J, Ten Eyck L, et al. Potential drug-drug interactions and opioid use among Medicare members with fibromyalgia and newly initiated on pregabalin or duloxetine. Poster presentation at the 33rd annual meeting of the American Pain Society, 30 April-3 May 2014, Tampa, FL, USA
50. Johnston SS, Udall M, Cappelleri JC, et al. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. Am J Health Syst Pharm 2013;70:2207-17
51. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49:661-9
52. Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison. Mayo Clin Proc 2011;86:615-26
53. Raskin P, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain 2014;30:379-90
54. Tanenberg RJ, Clemow DB, Giaconia JM, et al. Duloxetine compared with pregabalin for diabetic peripheral neuropathic pain management in patients with suboptimal pain response to gabapentin and treated with or without antidepressants: a post hoc analysis. Pain Practice 2014;14:640-8
55. Boyle J, Eriksson MEV, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012;35:2451-8
56. Bansal D, Bhansali A, Hota D, et al. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009;26:1019-26
57. Devi P, Madhu K, Ganapathy B, et al. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol 2012;44:51-6
58. Study 1008-040. Data on file, Pfizer Inc
59. Patel N, Mishra V, Patel P, et al. A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. J Diabet Metab Disord 2014;13:62
60. Razazian N, Baziyar M, Moradian N, et al. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences 2014;19:192-8
61. Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an openlabel, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25:1663-76
62. Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 2012;28:1027-37